

## India : India Responsive COVID-19 Vaccines for Recovery

### 1. Project Information

Project ID:	P000564	Instrument ID:	L0564A
Member:	India	Region:	Southern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:500.00 US Dollar million <input type="checkbox"/> Guarantee	Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Finance, India
Implementing Entity:	Ministry of Health and Family Welfare, India		
Project Team Leader:	Ankur Agrawal (Responsible DG: Rajat Misra; Responsible Department: INF1)		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Rabindra Shah, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Hari Bhaskar, Team Member; Christopher Damandl, Project Counsel; Aditi Khosla, Alternate Counsel; Jinghui Li, Project admin		
Completed Site Visits by AIIB:			
Planned Site Visits by AIIB:	Dec, 2022 Meeting with the implementing agency is planned in December 2022		
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	0		
Previous Red Flags Assigned Date:	2022/06		

### 2. Project Summary and Objectives

The objective of the Project is to vaccinate eligible populations against COVID-19 in the selected states of India (project states).

The Project will support the procurement of safe and effective vaccines against COVID-19. The project has been co-financed with the Asian Development Bank (ADB) under the rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD 2.058 billion, for which AIIB finances USD500 million (24.30 percent), ADB finances USD1.5 billion (72.89 percent) and the Government of India (GoI) finances the remaining USD 57.77 million (2.81 percent). The loan proceeds from AIIB and ADB will finance expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoI fund will cover financial charges during implementation, including interest, commitment charges and front-end fee. The GoI will also provide in-kind contributions in the form of counterpart staff, logistics, cold chain infrastructure, and other facilities.

The Project is expected to procure at least 667 million doses of vaccines, which will be administered to a target

population by 2024 in accordance with the current National Deployment Vaccine Plan (NDVP) for COVID-19 vaccines and any subsequent guidelines. The Project is to benefit at least 317 million people.

**3. Key Dates**

Approval:	Jan. 20, 2022	Signing:	Jan. 21, 2022
Effective:	Feb. 10, 2022	Restructured (if any):	
Orig. Closing:	Jun. 30, 2025	Rev. Closing (if any):	

**4. Disbursement Summary (USD million)**

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	372.29	Most recent disbursement (amount/date):	40.01/Nov. 07, 2022
Undisbursed:	127.71	Disbursement Ratio (%) <sup>1</sup> :	74.46

**5. Project Implementation Update**

About 75% of the loan has been disbursed with the last disbursement of USD40.01 million in November 2022. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	About 75% of the loan has been disbursed with the last disbursement of USD40.01 million on November 2022. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.	Under ADB's Safeguard Policy Statement (SPS), the project has been categorized as C for Environment, Involuntary Resettlement, and Indigenous Peoples on the basis that no adverse ES impacts are expected. No standalone safeguards monitoring report is required since the project is categorized C for all E&S aspects. However, according to the Updated Project Administration Manual, the Q4 progress report is expected to also document and assess the COVID-19 immunization waste management system's adequacy, quality of performance, and corrective actions planned to improve its effectiveness, as needed. The findings shall be reflected in the next PIMR.	All vaccine procurement contracts have been accomplished under the scope of AIIB financing. No further procurement contracts are due under AIIB's scope. Two manufactures were selected for manufacture and supply of vaccines and have been supplying the vaccines.

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

**Financial Management:**

As per the Financial Management Action Plan, an internal audit report is due. The audited project financial statement for FY21-22 has been overdue since September 30, 2022 and is expected to be completed in Q1FY23.

**6. Status of the Grievance Redress Mechanism (GRM)**

Ministry of Health and Family Welfare (MOHFW) has been operating a toll free 24x7 national helpline '1075' and another helpline (011-23978046) for addressing queries related to the COVID- 19 pandemic, vaccine rollout and the Co-WIN software. In addition to 1075, a technical helpline (0120-4473222) has been established to specifically handle Co-WIN software-related queries. Any technical issue which is not resolved by 1075 is directed to the Technical Helpline for resolution. MOHFW has also created an email ID (ncov2019@gov.in) for addressing COVID-19 related queries and grievances in addition to providing a repository of state COVID-19 helplines and website links for relevant resources, on its website - <https://www.mohfw.gov.in/>. State 104 helplines have been augmented to address queries on COVID-19 vaccination including grievance redressal related to vaccination process as well as linking to concerned facilities for management of any adverse event. As per guidelines, all grievances are to be reviewed at regular intervals at the level of state task force, district task force, urban task force, and block task force.

As a meeting with MOHFW is scheduled in December 2022, any updates on the GRM shall be reflected in the next PIMR.

**7. Results Monitoring**

Results shall be monitored in due course.

**Project Objective Indicators #1**

At least 317 million targeted people (at least 47.5% women) vaccinated with at least two doses against COVID-19 in project states.

Year	Target	Actual	Comments, if any
Aug. 16, 2021	-	-	Baseline: male: 52.6%, female:46.8%, others: 0.6%
Dec. 31, 2022	-	-	
Dec. 31, 2023	-	-	
Dec. 31, 2024	317 million, 47.5% of them women	-	

**Project Objective Indicators #2**

By 2024, at least 667 million doses of COVID-19 vaccine procured and delivered to the project states.

Year	Target	Actual	Comments, if any
Aug. 16, 2021	-	-	Baseline: 0
Dec. 31, 2022	-	-	
Dec. 31, 2023	-	-	

---

Dec. 31, 2024	667 million doses	-	
---------------	-------------------	---	--

**Remarks:**

---